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Abstract
Objectives: Pemetrexed is a thymidylate synthase (TS) inhibitor and is effective in non-small cell lung cancer (NSCLC). 39-
deoxy-39-[18F]fluorothymidine (18F-FLT), a proliferation marker, could potentially identify tumor specific TS-inhibition. The
aim of this study was to investigate the effect of pemetrexed-induced TS-inhibition on 18F-FLT uptake 4 hours after
pemetrexed administration in metastatic NSCLC patients.
Methods: Fourteen NSCLC patients underwent dynamic 18F-FLT positron emission tomography (PET) scans at baseline and
4 hours after the first dose of pemetrexed. Volumes of interest were defined with a 41%, 50% and 70% threshold of the
maximum pixel. Kinetic analysis and simplified measures were performed. At one, two, four and six hours after pemetrexed,
plasma deoxyuridine was measured as systemic indicator of TS-inhibition. Tumor response measured with response
evaluation criteria in solid tumors (RECIST), time to progression (TTP) and overall survival (OS) were determined.
Results: Eleven patients had evaluable 18F-FLT PET scans at baseline and 4 hours after pemetrexed. Two patients had
increased 18F-FLT uptake of 35% and 31% after pemetrexed, whereas two other patients had decreased uptake of 31%. In
the remaining seven patients 18F-FLT uptake did not change beyond test-retest borders. In all patients deoxyuridine levels
raised after administration of pemetrexed, implicating pemetrexed-induced TS-inhibition. 18F-FLT uptake in bone marrow
was significantly increased 4 hours after pemetrexed administration. Six weeks after the start of treatment 5 patients had
partial response, 4 stable disease and 2 progressive disease. Median TTP was 4.2 months (range 3.0–7.4 months); median OS
was 13.0 months (range 5.1–30.8 months). Changes in 18F-FLT uptake were not predictive for tumor response, TTP or OS.
Conclusions: Measuring TS-inhibition in a clinical setting 4 hours after pemetrexed revealed a non-systematic change in 18F-
FLT uptake within the tumor. No significant association with tumor response, TTP or OS was observed.
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Introduction
Non-small cell lung cancer (NSCLC) often presents in an
advanced stage. Unfortunately, treatment options are limited at
this stage, including chemotherapy with or without radiotherapy
[1] and targeted therapies [2]. Therefore, despite new drugs and
personalized therapy, treatment of metastatic NSCLC remains
challenging.
Pemetrexed, an anticancer drug with clinical efficacy in non-
squamous NSCLC, inhibits thymidylate synthase (TS) [3],
dihydrofolate reductase (DHFR), and glycinamide ribonucleotide
formyltransferase (GARFT) [4]. It is used as first line treatment in
combination with cisplatin or carboplatin and as monotherapy in
second line treatment in metastatic NSCLC. In the literature,
response rates of pemetrexed vary between 10–30% [5]. Level of
TS expression showed an inverse correlation with pemetrexed
sensitivity [6]. Pemetrexed has several side-effects such as nausea,
anemia, bone marrow depression, stomatitis, pharyngitis and rash
[7,8], which can be severe. Toxicities could be reduced in non-
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responding patients if effectiveness would be predictable, prefer-
ably in an early stage, e.g. from positron emission tomography
(PET) measurements.
39-deoxy-39-[18F]fluorothymidine (18F-FLT) PET could func-
tion as non-invasive biomarker of TS-inhibition effectuated by
pemetrexed. TS is a key enzyme for the synthesis of deoxyribo-
nucleic acid (DNA) and as such a target for anticancer drugs.
Figure 1 visualizes the cellular pathway of thymidine, which
consists of the de novo and the salvage pathway. TS is the essential
enzyme in the de novo pathway of thymidine nucleotides. When
the de novo pathway is down regulated by a TS inhibitor
(pemetrexed), DNA synthesis will depend on the salvage pathway,
which will be up regulated, facilitated by redistribution of the
equilibrative nucleoside transporter (ENT) to the cell membrane
[9]. Figure 1 indicates the interaction of pemetrexed, which is TS
inhibition. 18F-FLT follows the salvage pathway of endogenous
thymidine, which also provides thymidine nucleotides. However,
unlike endogenous thymidine, 18F-FLT is trapped in the cytosol
and is not incorporated into DNA. The uptake of 18F-FLT will
increase as a result of the up regulation of the salvage pathway,
when TS is effectively inhibited. In addition, inhibition of
thymidylate synthase will lead to accumulation of deoxyuridine
monophosphate which will be broken down to deoxyuridine and
released to the extracellular compartment and plasma. An increase
of plasma deoxyuridine after TS inhibition treatment may be
considered as a systemic surrogate marker of TS-inhibition. 18F-
FLT PET could monitor tumor specific changes of 18F-FLT
uptake after TS-inhibiting treatment [9].
The first clinical study of imaging drug-induced TS-inhibition
showed an increased [11C]thymidine uptake one hour after
nolatrexed (TS-inhibitor) administration in gastrointestinal cancer
patients [10]. A mouse model (fibrosarcoma) showed that 18F-FLT
PET allows early measurement of TS-inhibition caused by 5–
fluorouracil, with a 1.8 fold increase of 18F-FLT uptake 1–2 hours
after treatment [11]. This increase coincided with a twofold
increase in deoxyuridine accumulation in plasma. Hence, 18F-FLT
PET appears suited for non-invasive assessment of TS-inhibition
in tumors.
Since 18F-FLT signal harbours combined information of
proliferation and TS-inhibition, appropriate timing of PET after
administration of pemetrexed is important: if applied too late, the
proliferation signal may dominate (a decline in case of response),
whereas the actual TS-inhibition may be most prominent within
the first 24 hours. Preclinical 18F-FLT PET data was derived two
hours after intervention. Earlier data [12] suggested that this time-
schedule could be extended in patients since the deoxyuridine
accumulation is present up to six hours, therefore, a PET scan
after 4 hours was chosen as the optimal time interval.
The aim of the present study was to investigate the effect of
pemetrexed-induced TS-inhibition on 18F-FLT uptake 4 hours
after pemetrexed administration in patients with metastatic
NSCLC.
Materials and Methods
Patients
Fourteen patients with histological confirmed NSCLC adeno-
carcinoma were included prospectively. Patients were recruited
from the VU University Medical Center in Amsterdam, The
Netherlands. Patients had to be $18 years old, scheduled for
treatment with pemetrexed and had a tumor of $3 cm in
diameter within the chest. Prior to study enrolment, all patients
signed a protocol-specific informed consent. Patients were staged
according to the 7th TNM classification system developed by
International Association for the Study of Lung Cancer [13] and
the Eastern Cooperative Oncology Group (ECOG) performance
status [14] were determined. Patients underwent 18F-FLT PET
scanning within one week before the start of treatment with
pemetrexed and 4 hours after the first therapeutic pemetrexed
dose, which consisted of 500 mg?m22. 18F-FLT PET scans and
deoxyuridine measurements were performed after pemetrexed as
single agent. Combination therapy with cisplatin (75 mg?m22) or
carboplatin (AUC 5) was given one day later to avoid interference
with 18F-FLT uptake. Treatment schedule was according to
standard practice, which is every 3 weeks. The study was approved
by the medical ethics review committee of the VU University
Medical Center.
PET Imaging
PET scans were performed using an ECAT EXACT HR+
scanner (Siemens/CTI), which consists of 32 rings of bismuth
germanate oxyorthosilicate (BGO) detectors [15]. This scanner
enables the acquisition of 63 planes of data over a 15.5 cm axial
field of view. Two venous cannula were inserted: one was used for
tracer injection and the other for blood sampling.
Figure 1. Cellular pathway of thymidine with the interaction of pemetrexed indicated. 18F-FLT is not incorporated into DNA, as shown by
the dotted arrow. Abbreviations: ENT, Equilibrative Nucleoside Transporter; TMP, Thymidine Monophosphate; TDP, Thymidine Diphosphate; TTP,
Thymidine Triphospate; dNT, deoxyribonucleotidase.
doi:10.1371/journal.pone.0063705.g001
[18F]FLT PET in NSCLC
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First, a 10 minute transmission scan was performed using three
retractable rotating line sources. These data were used to correct
the subsequent emission scans for photon attenuation. Following
the transmission scan, a target dose of 250 MBq 18F-FLT was
injected intravenously, 30 seconds after starting a dynamic
emission scan in 3D setting with a total scan time of 60.5 minutes
and with the following frame lengths: 665 s, 6610 s, 3620 s,
5630 s, 5660 s, 86150 s, and 66300 s. All emission scans were
reconstructed using filtered back projection (FBP) with a 0.5
Hanning filter, resulting in a transaxial spatial resolution of
,7 mm in the center of the field of view.
Venous samples were drawn at 5, 10, 20, 30, 40 and 60 minutes
after 18F-FLT injection. Whole blood and plasma activity was
measured immediately, as were plasma metabolite fractions.
Table 1. Patient demographics and characteristics.
Characteristics Total no. of patients n=14 (%) PET evaluable patients n=11 (%)
Sex Male 6 (43) 3 (27)
Female 8 (47) 8 (73)
Age (years) Median 59 61
Range 35–77 35–77
TS polymorphism 2R2R 5 (35.7) 4 (36.4)
3R3R 3 (21.4) 2 (18.2)
2R3R 4 (28.6) 4 (36.4)
Missing data 2 (14.3) 1 (9.1)
MTHFR polymorphism 677C 6 (42.9) 5 (45.5)
677T 3 (21.4) 3 (27.3)
C677T 3 (21.4) 2 (18.2)
Missing data 2 (14.3) 1 (9.1)
Chemotherapy Pemetrexed 1 (7.1) 1 (9.1)
Pemetrexed/carboplatin 7 (50) 5 (45.5)
Pemetrexed/cisplatin 6 (42.9) 5 (45.5)
RECIST Complete response 0 (0) 0 (0)
Partial response 5 (35.7) 5 (45.5)
Stable disease 7 (50.0) 4 (36.4)
Progressive disease 2 (14.3) 2 (18.2)
TTP (months) Median 4.3 4.2
Range 3.0–10.4 3.0–7.4
Overall Survival (months) Median 9.7 13.0
Range 5.1–32.7 5.1–30.8
Abbreviations: TS, Thymidylate Synthase; MTHFR, methylenetetrahydrofolate reductase; RECIST, Response Evaluation Criteria in Solid Tumors; TTP, Time To Progession.
doi:10.1371/journal.pone.0063705.t001
Table 2. Results of standardized uptake value, non linear regression and Patlak Ki analysis per scan.
Baseline Median (range) 4 hours after pemetrexed administration Median (range)
SUV 3.7 (2.2–8.0) 4.0 (1.7–8.9)
NLR 3k K1 0.201 (0.010–0.353) 0.171 (0.095–13.30)
NLR 3k k2 0.103 (0.009–0.647) 0.098 (0.049–0.175)
NLR 3k k3 0.026 (0.011–0.161) 0.022 (0.012–0.041)
NLR 3k Ki 0.032 (0.010–0.079) 0.031 (0.010–0.060)
NLR 4k K1 0.256 (0.019–0.443) 0.220 (0.123–11.40)
NLR 4k k2 0.267 (0.042–1.230) 0.169 (0.045–0.324)
NLR 4k k3 0.081 (0.011–1.350) 0.038 (0.011–0.161)
NLR 4k k4 0.020 (0.000–0.032) 0.006 (0.000–0.032)
NLR 4k Ki 0.048 (0.010–0.136) 0.035 (0.023–0.076)
Patlak Ki 0.026 (0.009–0.061) 0.028 (0.010–0.52)
doi:10.1371/journal.pone.0063705.t002
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PET Data Analysis
The primary lesion was identified in all patients. Volume of
interest (VOI) were defined using a semiautomatic threshold
technique on the summed last 3 frames, which were reconstructed
using ordered subset expectation maximisation reconstruction with
2 iterations and 16 subsets and 5 mm full width at half maximum
(FWHM) Gaussian smoothing. The VOI thresholds 41% and 70%
of the maximum pixel corrected for background, and 50%
corrected and uncorrected for background were analysed, together
with the maximal pixel in the VOI. Tumor VOIs were transferred
to FBP reconstructed dynamic 18F-FLT images to generate time-
activity curves (TAC).
An image-derived input function (IDIF) was obtained by
manually drawing 2-dimensional regions of interest over the
aortic arch, aorta ascendens and aorta descendens on FBP
reconstructed images, these were then applied to all frames to
generate an IDIF. The IDIFs were corrected for plasma-to-blood
ratio and parent fractions to obtain metabolite corrected plasma
input functions.
For each VOI, several (semi)quantitative methods were
calculated using Matlab (Natick, MA). Standardized uptake values
(SUV) were calculated for the interval 40–60 minutes and 50–60
minutes, normalised to body weight, lean body mass and body
surface area. Total lesion proliferation (TLP) was calculated as
metabolic volume *SUV. Full kinetic analysis with non linear
regression (NLR), using irreversible and reversible two tissue
compartment models with 3 and 4 parameters respectively, were
included, together with blood volume fraction. Patlak analysis
[16], assuming an irreversible model and resulting in net uptake
rate Ki, with the time intervals 10–60 minutes, 10–45 minutes, 10–
30 minutes, 20–60 minutes and 30–60 minutes were assessed.
Volume of distribution was calculated as K1/k2*(1+k3/k4), with
the parameters derived from NLR with 4 kinetic rate constants.
In addition, mean SUV corrected for bodyweight were
calculated for muscle, liver, bone marrow and lung tissue, as
non-tumor reference tissue. These VOI were placed manually
over the designated tissue in a standardized manner (muscle 363
voxels in 5 planes, liver 767 voxels in 5 planes, bone marrow 262
voxels in 5 planes, lung 363 voxels in 5 planes).
Deoxyuridine Measurements in Plasma
Plasma samples for deoxyuridine were taken at least one week
and one minute before the first dose of pemetrexed, functioning as
double baseline measurements. Subsequently, samples were taken
one, two, four and six hours after pemetrexed to determine the
deoxyuridine plasma concentration over time. Deoxyuridine (ng/
ml) was measured with a validated liquid chromatography with
tandem mass spectrometry detection (LC-MS/MS) assay as
described earlier [17,18].
Immunohistochemistry
The procedure for immunohistochemistry (IHC) for TS
expression was slightly modified from Van Triest [19]. Thymily-
date synthase mouse monoclonal Mouse Clone TS106, DAKO,
1/100, for 1 hr at room temperature. Detection system Power-
Vision was used. TS expression was scored quantitatively with the
H-score in nucleus and cytoplasma. H-score was scored as g(I6
PC), where I represents the staining intensity and PC the
percentage of cells that stain at each intensity. The median H-
score of the included patients was used as cut-off value for low and
high TS expression classification.
TS and Methylenetetrahydrofolate Reductase (MTHFR)
Polymorphism
TS and MTHFR polymorphism are prognostic factors in
NSCLC [20]. Isolated leucocytes from the first blood sample were
used to determine TS and MTHFR polymorphism with real time
polymerase chain reaction [21]. We defined 2R2R, 2R3R and
3R3R polymorphism for TS and 677C, 677T and C677T for
MTHFR.
Figure 2. Correlation between SUV and Patlak at baseline and
4 hours after pemetrexed administration.
doi:10.1371/journal.pone.0063705.g002
Table 3. Plasma to blood ratio and parent fraction per scan.
Baseline PET PET 4 hours after pemetrexed administration
Time (min)
Plasma to blood ratio Median
(range) Parent fraction Median (range)
Plasma to blood ratio Median
(range) Parent fraction Median (range)
5 1.075 (1.049–1.103) 98.49 (97.01–99.42) 1.075 (1.050–1.095) 98.36 (96.67–99.56)
10 1.085 (1.057–1.154) 95.75 (90.38–98.11) 1.093 (1.031–1.128) 95.64 (91.33–97.07)
20 1.116 (1.043–1.159) 90.62 (84.88–95.49) 1.119 (1.048–1.154) 90.03 (73.85–94.20)
30 1.148 (1.073–1.204) 86.70 (78.51–91.12) 1.142 (1.076–1.174) 83.21 (76.76–88.41)
40 1.166 (1.067–1.224) 83.28 (77.95–88.26) 1.167 (1.091–1.216) 79.91 (69.01–85.69)
60 1.185 (1.097–1.209) 80.55 (75.36–85.21) 1.191 (1.110–1.224) 79.15 (67.26–83.70)
doi:10.1371/journal.pone.0063705.t003
[18F]FLT PET in NSCLC
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Clinical Outcome
Tumor response was evaluated after six weeks on computed
tomography (CT) according to response evaluation criteria in solid
tumors (RECIST) [22]. Furthermore, time to progression (TTP)
and overall survival (OS) were defined as the start of treatment
with pemetrexed until the first observation of tumor progression
and the day of death, respectively.
Statistical Analysis
The primary outcome was the absolute and relative difference
of 18F-FLT uptake measured with SUV and full kinetic analysis 4
hours after the first dose of pemetrexed beyond earlier established
test-retest boundaries [23]. The differences in 18F-FLT uptake
were correlated with clinical outcome measured as tumor
response, TTP and OS. Variables were tested for normality to
decide for parametric or nonparametric statistics and a p-value
,0.05 was considered significant. Statistical analysis consisted of
paired t-test, Wilcoxon signed-rank test and Kruskal-Wallis test.
The median value for TTP and OS was calculated with Kaplan
Meier. All statistical analyses were performed using SPSS 15.0.
Results
Patients
Fourteen NSCLC patients with stage IV disease were included.
Performance score was 0–1 for all patients, median age was 59 and
six patients were male. Three patients were treatment naı¨ve,
eleven patients had 1st line treatment and three patients had 2nd
line chemotherapy before treatment with pemetrexed. None of the
patients had radiotherapy targeted on the index lesions. After
study enrolment seven out of fourteen patients received peme-
trexed in combination with carboplatin, six in combination with
cisplatin and one patient received pemetrexed monotherapy.
Figure 3. [18F]FLT PET scan. Example of 18F-FLT uptake (A) before and (B) 4 hours after pemetrexed administration, showing an increase of 18F-
FLT uptake in the primary tumor (arrow) of 32% after pemetrexed administration.
doi:10.1371/journal.pone.0063705.g003
Figure 4. Change of 18F-FLT uptake. Change of 18F-FLT uptake in SUV 40–60 min normalised to bodyweight (A) absolute difference, (B)
percentage difference.
doi:10.1371/journal.pone.0063705.g004
[18F]FLT PET in NSCLC
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PET Scans
From the fourteen included patients, eleven patients were
evaluable for deriving changes in 18F-FLT (see Table 1 for
descriptive statistics). Three patients were not evaluable due to: (1)
technical errors with the PET scanner, (2) insufficient tracer
production, and (3) non-evaluable kinetic parameters for the
second 18F-FLT PET scan. 18F-FLT dosage ranged from 226–278
MBq. From the tested VOI, 50% corrected for background was
most suitable, because it was feasible for all but one lesion and has
been shown to be the VOI of preference as described in previous
work [24]. In addition, study conclusions were not affected by
VOI method. Therefore, further results shown are based on the
VOI 50% with background correction and normalised to body
weight.
Kinetic analysis was performed to validate SUV against full
quantitative measures (e.g. Ki obtained using non linear regression
and Patlak analysis). Table 2 shows the median kinetic parameters
for the reversible and irreversible NLR model, Patlak analysis and
SUV for the paired scans. The reversible two tissue compartment
model with 4 parameters was the model of choice for NLR as
indicated by the Akaike and Schwarz criteria [25] in 7 out of 11
(64%) for the baseline scans. For the scans 4 hours after
pemetrexed administration Akaike indicated the best fit with the
reversible two tissue compartment model in 8 out of 11 (73%) and
Schwarz in 7 out of 11 (64%) scans. NLR Ki results shown in this
paper are therefore based on the reversible two tissue compart-
ment model with 4 kinetic rate constants.
The median volume of distribution, derived from NLR 4k was
4.1 ml?cm23 and 6.7 ml?cm23 for baseline and 4 hours after
pemetrexed administration respectively (Wilcoxon signed-rank test
p = 0.60). The correlation between SUV and Ki derived from
Patlak with different time intervals was moderate, with R-squares
varying from 0.7–0.8. Figure 2 shows the correlation between
SUV and Patlak Ki 10–60 minutes before and after treatment with
pemetrexed. No statistical difference in the correlation between
SUV and Patlak was found before and after the start of treatment
with pemetrexed. Therefore SUV could be used to measure 18F-
FLT uptake differences in this setting.
The median plasma to blood ratio and parent fraction for
baseline and 4 hours after pemetrexed administration are shown in
table 3. The median plasma to blood ratio ranged from 1.075–
1.191. Twenty percent of 18F-FLT is glucuronidated in the liver at
sixty minutes after 18F-FLT administration. There was no
significant difference in plasma to blood ratio or parent fraction
between the two scans.
In two patients, 18F-FLT tumor uptake significantly increased
(31 and 35%) 4 hours after therapy compared with baseline
(beyond test-retest borders of 15% [23]), while two other patients
showed a significant decrease (31%). Figure 3 shows an example of
a 18F-FLT PET scan of a patient with increased 18F-FLT uptake
after pemetrexed administration. In the remaining seven patients,
Figure 5. Mean SUV in muscle, liver, bone marrow and lung. Mean SUV normalised to bodyweight for muscle, liver, bone marrow and lung at
baseline and 4 hours after pemetrexed.
doi:10.1371/journal.pone.0063705.g005
[18F]FLT PET in NSCLC
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the change in 18F-FLT uptake was within the test-retest variability
(see Figure 4). In Table 4 the results for the two 18F-FLT PET
scans and the clinical outcome are listed per patient. The median
SUV at baseline and 4 hours after pemetrexed administration
were 3.89 and 3.78 (Wilcoxon signed-rank test p = 0.79). Median
volume of the VOI at baseline was 11.6 ml, and 10.5 ml 4 hours
after pemetrexed administration (p = 0.93). Median TLP was 38.5
and 37.8 for baseline and 4 hours after pemetrexed administration
respectively (p = 0.42). Mean SUV in muscle, liver, bone marrow
and lung are shown in Figure 5. Bone marrow exclusively showed
a significant increase of 18F-FLT uptake of 33%, 4 hours after
pemetrexed administration (p,0.01).
Clinical Outcome
After six weeks, response evaluation according to RECIST
revealed no patients with complete response (CR), five patients
with partial response (PR), seven with stable disease (SD) and
two with progressive disease (PD). Baseline SUV was not
predictive for tumor response (Kruskal-Wallis test p = 0.86).
Tumor response for the eleven PET evaluable patients revealed
5 patients with PR, 4 SD and 2 PD. The mean SUV
differences per tumor response group are shown in Figure 6A.
DSUV was not related with RECIST (Kruskal-Wallis test
p = 0.59). In addition, differences in Patlak Ki, NLR Ki, k3 or
volume of distribution was not related with RECIST (Kruskal-
Wallis test p.0.05).
The median TTP was 4.3 months, with a range of 3.0–10.4
months for the complete study population. Baseline SUV from
these fourteen patients and TTP were not associated (Cox
regression p = 0.54). For the eleven PET evaluable patients the
median TTP was 4.2 months, with a range of 3.0–7.4 months.
There was no significant association between the difference in
SUV and TTP (Log rank, p = 0.96). The median OS was 9.7
months (range 5.1–32.7 months) for the complete group and
13.0 months (range 5.1–30.8 months) for the PET evaluable
patients. SUV baseline nor SUV difference were associated with
OS (Cox regression, Log rank p = 0.74 and 0.43, respectively).
Figure 6. Box plots with absolute differences in SUV. SUV 40–60 min normalised to bodyweight for (A) tumor response after 6 weeks, (B)
immunohistochemistry thymidylate synthase expression, (C) thymidylate synthase polymorphism, (D) methylenetetrahydrofolate reductase
polymorphism.
doi:10.1371/journal.pone.0063705.g006
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Deoxyuridine
Paired baseline deoxyuridine measurements in plasma showed
a consistent value with a mean 6 standard deviation of
12.667.9 and 11.566.0 ng/ml respectively (paired t-test
p = 0.995). One hour after administration of pemetrexed
deoxyuridine levels significantly rose in all patients (p,0.05)
and this persisted until six hours after administration of
pemetrexed (see Figure 7). No significant difference in
deoxyruridine between one, two, four and six hours after
administration of pemetrexed was observed.
Immunohistochemistry
IHC for TS was performed in 12 patients. Median H-score was
105 in nucleus and 70 in cytoplasm. Figure 8 illustrates IHC of low
and high TS expression. Mean SUV differences for low and high
TS expression are shown in Figure 6B (Mann Withney U test
p = 0.91).
TS and MTHFR Polymorphism
TS and MTHFR polymorphisms have been determined for
twelve patients. For TS the polymorphisms 2R2R, 2R3R and
3R3R were defined, with respectively five, three and four
patients per group. MTHFR polymorphism showed six patients
with 677C, three patients with 677T and three patients with
C677T. The mean SUV differences per polymorphism are
shown in Figure 6C–D. No significant difference in SUV for TS
or MTHFR polymorphism was observed (Kruskal-Wallis test
p = 0.11 and p = 0.86 respectively). TS or MTHFR polymor-
phism were not prognostic for tumor response, TTP or OS (Chi
square and Kruskal-Wallis p.0.05).
Low or high TS expression measured with IHC correlated with
TS polymorphism (Chi-Square p = 0.03). H-score was significantly
higher in patients with 2R3R and 3R3R polymorphism compared
to 2R2R (Jonckheere-Terpstra p = 0.04). IHC TS expression did
not correlate with MTHFR polymorphism (Chi-square p = 0.44).
Discussion
The present study evaluated the potential of measuring TS-
inhibition with 18F-FLT PET in NSCLC patients treated with the
TS inhibitor pemetrexed. From biologic understanding and
preclinical studies, an increase of 18F-FLT uptake is expected
after pemetrexed administration in responding patients if clinical
response is mainly attributed to TS-inhibition. Our data shows
that two out of eleven patients had an increased 18F-FLT uptake 4
hours after administration of pemetrexed beyond test retest
boundaries (15% for SUV) [23,24]. These two patients had PR
measured with RECIST after 6 weeks. However, increased 18F-
FLT uptake did not correlate with longer TTP or OS.
Two patients showed an unexpected decrease in 18F-FLT
uptake. The biological explanation for this is unclear. The time-
interval of 4 hours should be too short to show the effect of
decreased proliferation, although pemetrexed is also known to
increase TS function [12,12,21], lowering its inhibition and hence
possibly decrease 18F-FLT uptake. The decreased uptake may in
addition be explained by reduced perfusion, but we can only
speculate this since we did not measure perfusion in this study. K1
Figure 7. Plasma deoxyuridine over time. *Significant differences
tested with paired t-test, p,0.05, indicated by the accolade.
doi:10.1371/journal.pone.0063705.g007
Figure 8. Thymidilate synthase immunohistochemistry (206). In (A) scattered nuclear staining in .50% nuclei, and in (B) around 10% of the
nuclei. Note in (A) also concomitant scattered cytoplasmic staining.
doi:10.1371/journal.pone.0063705.g008
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in these patients were not significantly lowered compared to
baseline or to other study patients.
Full kinetic analysis, NLR and Patlak analysis, were evaluated in
this study. Correlation between Patlak and SUV was moderate,
but did not change between the two scans. Use of NLR, Paltak or
volume of distribution did not change our study results compared
to SUV.
The full kinetic data showed a reversible two tissue compart-
ment model with 4 rate constants, as determined by Akaike and
Schwarz. In the literature an irreversible model for 18F-FLT up to
60 minutes has been reported as preferred model [26,27]. Muzi
et al. reported the influence of k4 after 90 minutes, implicating a
reversible model at that time point [28]. In our study, 7 out of 11
patients had a better fit with a reversible two tissue compartment
model. This suggests that k4 is different from zero in the majority
of the patients in our study population within 60 minutes after
injection.
Deoxyuridine plasma levels increased after pemetrexed admin-
istration in all patients, which implicates global TS-inhibition. This
is in agreement with earlier studies on pemetrexed and other TS
inhibitors [29–31]. As this increase appeared in all patients,
deoxyuridine plasma levels were not able to distinguish which
patient had therapeutic TS-inhibition within the tumor. The
increase in deoxyuridine plasma levels is most likely due to
effective TS-inhibition in normal tissue. This is supported by
increased [18F]FLT uptake in bone marrow 4 hours after
pemetrexed administration, indicating effective TS inhibition at
this time interval. Bone marrow has low TS expression and
pemetrexed induced TS-inhibition has been shown to be most
effective in tissue with low TS expression [6]. Earlier it was
observed in an animal model in bone marrow, that TS was
inhibited efficiently by 5FU treatment, but the same dose did not
affect liver [32,33]. Therefore bone marrow is likely to be highly
sensitive to TS inhibition by pemetrexed. As a result, hematologic
toxicities are also common in patients treated with pemetrexed.
Our study confirms early effective TS-inhibition in bone marrow
indicated by increased [18F]FLT uptake 4 hours after pemetrexed
administration. This non-tumor specific effect of TS-inhibition in
bone marrow may serve as a surrogate for other proliferating
tissues which clarifies the increased deoxyuridine levels in all
patients.
A previous study performed in breast cancer patients (n = 6)
revealed an increase in 18F-FLT uptake in all but one patient at
one hour after treatment with capecitabine [34]. No statistical
comparison with clinical outcome was performed. This study in
breast cancer patients is the only study with 18F-FLT PET scans
performed within one day after the start of treatment. The findings
in 18F-FLT uptake differ from our study results. However, the
studies cannot be compared since they evaluate different tumor
types, different time intervals and different treatments. In addition,
as a 5-FU prodrug, capecitabine has different actions beside TS-
inhibition; its metabolic pathway may interfere with thymidine
metabolism.
It could be argued that lack of correlation between 18F-FLT
PET and clinical outcome resulted from inappropriate timing of
imaging. The time interval for 4 hours was based on earlier studies
with various antifolate TS inhibitors, which showed an optimal
increase between 1–4 hr for BGC9331 but between 4–24 hr for
another antifolate BGC 945 [31]. However, the optimal time point
of scanning might not be 4 hours after pemetrexed administration.
In addition, acquired drug resistance to therapy could affect the
relationship between in principle an effective pharmacodynamic
imaging biomarker and the ultimate clinical outcome in time to
progression and overall survival.
The response assessment has limitations, as only one patient
received pemetrexed monotherapy and the other patients had
combination therapy including cisplatin or carboplatin. These
differences in therapy affect the clinical outcome. PD after six
weeks proofs the lack of therapeutic effect of pemetrexed, but PR
could be attributed to the combination therapy with cisplatin or
carboplatin. In addition, the clinical outcome can be influenced by
lesions outside the field of view of the dynamic 18F-FLT PET scan,
which is 15.5 cm in the thoracic region.
The limitations of the tracer 18F-FLT should be considered. 18F-
FLT can be in competition with endogenous thymidine. In
addition, uptake of 18F-FLT is S-phase specific and dependent on
the presence of transporter ENT1 and the expression and activity
of thymidine kinase 1. Contractor et al. [35] published results of
the role of up- and downregulation of the ENT transporter, the
most important transporter of 18F-FLT into the cell. Soloviev et al.
[11] highlighted the limited knowledge of the possible changes in
tumors of essential enzymes and transporters involved in the
salvage pathway of thymidine after treatment. These still unknown
aspects of the biochemical pathway of 18F-FLT could affect our
study results and should be addressed in future research.
Patients with 2R3R and 3R3R polymorphism showed higher
H-scores compared to 2R2R polymorphism, confirming the
relation between TS polymorphism and TS expression [36]. TS
immuhistochemistry was performed in a standardized way.
Unfortunately some limitations apply these measurements. For
example, in five patients only metastatic tumor tissue was
evaluable because it was technically not feasible to biopsy the
primary lung lesion. TS expression in metastasis could differ from
the primary. Another limitation is the time-interval between
biopsy and 18F-FLT PET, this ranged from 1 week to several
months. TS expression could change over time. These limitations
should be considered interpreting the results from TS expression
measured with immuhistochemistry.
TS and MTHFR polymorphism did not correlate with
difference in SUV or clinical outcome, but this study was not
powered to evaluate this. Therefore, although this pilot study
could not confirm it, the correlation between TS and MTHFR
polymorphism status and clinical outcome might exist.
Conclusions
Measuring TS-inhibition in a clinical setting 4 hours after
pemetrexed revealed a non-systematic change in tumor 18F-FLT
uptake, although systemic effects of TS-inhibition were clear. The
association with tumor response, time to progression or overall
survival was not significant. Further research on the biochemical
pathway and uptake patterns of 18F-FLT during therapy is needed,
including evaluation of the optimal time-interval for scanning.
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